Hair Loss

$4B+
Annual Treatment Market
25+
Years Since Last Approval
85%
Men With Thinning by Age 50
0
FDA Cures Approved

The Numbers

Androgenetic alopecia -- commonly called male and female pattern hair loss -- affects over 50 million people in the United States. The global market for hair loss treatments exceeds $4 billion annually. That market funds management. It does not fund cure research.

Two drugs have been approved for hair loss in the past 37 years. Both manage symptoms. Neither addresses the underlying cause: the sensitivity of hair follicles to DHT and their progressive miniaturization. The disease continues to progress exactly as it did in 1988 when minoxidil was approved.

Minoxidil Approval 1988
Finasteride Approval 1997
New Cure Approvals Since 0
What Current Drugs Do Slow hair loss

Promises vs. Reality

1988
Reality: Minoxidil approved as topical treatment. Does not stop hair loss. Slows it.
1997
Reality: Finasteride approved. Inhibits DHT conversion. Effective management tool. Not a cure.
2000s
Promise: Hair cloning and cell therapy research accelerates. Cure 5--10 years away. Repeated every year.
2010s
Promise: Platelet-rich plasma and stem cell therapy gain attention. Hair regeneration imminent.
2022
Reality: JAK inhibitors approved for alopecia areata. Different disease. Does not address pattern hair loss.
2024
Promise: New follicle regeneration studies begin. Clinical trials expected. Cure still 5--10 years away.

Current Research Status

Hair loss research has fragmented into multiple approaches: JAK inhibition, follicle cloning, cellular reprogramming, and growth factor delivery. None have produced a cure for androgenetic alopecia. Most remain in preclinical or early clinical stages.

The fundamental problem persists unchanged: restoring dormant follicles while the underlying cause -- DHT sensitivity and genetic predisposition -- remains active. Every approach must solve this dual problem or face the same limitations as minoxidil and finasteride.

Active Research Approaches 6+
Drugs in Trials (Androgenetic) 2--3
Time Since Last Approval 27 years
Cure Approvals (Androgenetic) 0

Sources & Methodology

Data compiled from FDA approval records, peer-reviewed dermatology literature, and clinical trial registries.

Primary Sources

  • FDA Center for Drug Evaluation and Research -- Hair Loss Drug Approvals Timeline
  • ClinicalTrials.gov -- Hair Loss Clinical Trials Registry (androgenetic alopecia)
  • Journal of the American Academy of Dermatology -- Pattern Hair Loss Research Reviews
  • FDA Documentation -- Minoxidil approval (1988) and Finasteride approval (1997)
  • Grand View Research -- Global Hair Loss Market Analysis (2024)
  • Nature Reviews -- Dermatology, Hair Follicle Biology and Disease (2020)
  • ClinicalTrials.gov -- JAK Inhibitor Trials for Alopecia (2022--present)